

Date th February



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718,
Website: www.biofilgroup.net

(Amount in Lakhs except EPS)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2022							
		Quarter Ended			Nine Month Ended		Year Ended
Sr No.	Particulars	3 months ended on 31/12/2022	Previous 3 months ended on 30/09/2022	Corresponding 3 months ended on 31/12/2021	Year to date figures for Current period ended 31/12/2022	Year to date figures for Previous Year ended 31/12/2021	Previous Year ended on 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited

XVIII	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
	(2) Diluted (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
XIX	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XX	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
	(2) Diluted (Rs)	0.06	0.03	0.21	0.22	0.45	0.44

The above unaudited financial results for the Quarter and nine month ended dec. 31, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors.




SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2022

		(Amount in Lakhs)				
S.No.	Segment Revenue	Quarter Ended			Nine Month Ended	
		3 Month Ended 31/12/2022	Preceeding 3 Month Ended 30/09/2022	Correspondin g 3 months ended in the previous year (31/12/2021)	Year to date figures for current period ended (31/12/2022)	Year to date figures for the previous year ended (31/12/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
						Previous Year ended March 31 2022 Audited
1	Segment Revenue					
	Pharma Unit	1.33	141.94	106.60	1,204.45	1,880.11
	Chemicals Division	148.11	120.02	56.42	437.50	193.58
						337.71
	Net Sales/ Income From Operations	149.44	261.96	163.02	1,641.95	2,073.68
						2,238.23
2	Segment Results					
	Pharma Unit	(11.95)	(13.87)	40.56	(28.59)	109.76
	Chemicals Division	26.35	21.00	4.04	78.78	(11.12)
						4.63
	Total Segment Profit Before Tax & Interest	14.40	7.13	44.61	50.19	98.64
						103.33
	Interest Income	0.03	0.01	0.53	0.05	1.58
	Finance Cost	1.06	1.05	1.09	3.23	3.03
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	13.37	6.08	44.04	47.01	97.19
						101.49
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	873.87	2,012.21	2528.41	873.87	2,528.41
	Chemicals Division	1,382.80	1,299.99	1196.39	1,382.80	1,196.39
	Total (A)	2,256.66	3,312.20	3,724.80	2,256.66	3,724.80
						1,873.22
	Segment Liabilities (B)					
	Pharma Division	346.31	1,454.74	1564.25	346.31	1,564.25
	Chemicals Division	191.71	148.51	464.95	191.71	464.95
						86.53
	Total (B)	538.02	1,603.26	2,029.20	538.02	2,029.20
						189.46
	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	527.56	557.47	964.16	527.56	964.16
	Chemicals Division	1,191.09	1,151.47	731.44	1,191.09	731.44
						591.56
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,718.64	1,708.94	1,695.60	1,718.64	1,695.60
						1,683.77

Date : 14-02-2023
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)






Independent Auditor's Review Report on the Quarterly Financial Statement and Year to

Date Standalone Financial Results of the



CHARTERED ACCOUNTANTS



MAHESHWARI & GUPTA
CHARTERED ACCOUNTANTS

